- Health Conditions
- Events
- Ask a Doctor
- Visit A Doctor
- HCP Portal
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Semaglutide
Novo Nordisk launches Wegovy in China, targeting the country’s 180 million people with obesity. Priced at ¥1,400 ($192 USD) per starter dose, it faces accessibility challenges as it’s not covered by national insurance. The move heightens competition with Eli Lilly.
Breakthrough Trial Suggests GLP-1 Drugs Could Slow Alzheimer’s Progression Researchers have discovered that GLP-1 drugs, like liraglutide, may slow cognitive…
The cosmetic consequences of using the diabetes medication Ozempic for off-label weight loss are becoming increasingly visible. Dubbed “Ozempic face,” this phenomenon describes the rapid ageing and sagging of facial skin seen in some users.
As the world shifts its focus from the immediate threat of the COVID-19 pandemic, another health concern, often silent but equally impactful, is gaining prominence. Non-alcoholic Fatty Liver Disease (NAFLD), recognised as the “silent epidemic,” has emerged as a significant global health issue, affecting an estimated 38% of the world’s population.
Log In or Register as a healthcare professional to read the full article.
Log In or Register as a healthcare professional to read the full article.
In the realm of healthcare and wellness, advancements in medical science continually push the boundaries of what is possible in managing chronic conditions. One such breakthrough in diabetes management is Ozempic.
Subscribe to Updates
Subscribe to receive latest health related news from us
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.